Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells $385,000.00 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $22.07 on Monday. The firm’s 50-day simple moving average is $21.26 and its 200-day simple moving average is $18.79. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.00 and a 1-year high of $24.27. The firm has a market cap of $2.63 billion, a P/E ratio of 18.70, a PEG ratio of 3.40 and a beta of 0.75.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after buying an additional 860,244 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after acquiring an additional 263,099 shares during the last quarter. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares during the period. Renaissance Technologies LLC increased its stake in Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after acquiring an additional 287,300 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Catalyst Pharmaceuticals by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock valued at $19,439,000 after purchasing an additional 22,860 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of recent research reports. Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Finally, Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.